MX9304435A - PHARMACEUTICAL COMPOSITION AND COMPOSITION FOR THE TREATMENT AND PROPHYLAXIS OF OBESITY OR FOR THE TREATMENT OF TYPE II DIABETES. - Google Patents
PHARMACEUTICAL COMPOSITION AND COMPOSITION FOR THE TREATMENT AND PROPHYLAXIS OF OBESITY OR FOR THE TREATMENT OF TYPE II DIABETES.Info
- Publication number
- MX9304435A MX9304435A MX9304435A MX9304435A MX9304435A MX 9304435 A MX9304435 A MX 9304435A MX 9304435 A MX9304435 A MX 9304435A MX 9304435 A MX9304435 A MX 9304435A MX 9304435 A MX9304435 A MX 9304435A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- prophylaxis
- composition
- obesity
- diabetes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describe un método para el tratamiento y/o la profilaxis de la obesidad o para el tratamiento de la diabetes del Tipo II en mamíferos, tales como humanos, que comprende administrar al mamífero en necesidad de tal tratamiento y/o profilaxis, una cantidad efectiva y/o profiláctica, no tóxica del Compuesto 1 (1,3-di-cicloprometil-8-amino-xantina).A method for the treatment and / or prophylaxis of obesity or for the treatment of Type II diabetes in mammals, such as humans, is disclosed which comprises administering to the mammal in need of such treatment and / or prophylaxis, an effective amount and / or prophylactic, non-toxic of Compound 1 (1,3-di-cyclopromethyl-8-amino-xanthine).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929215633A GB9215633D0 (en) | 1992-07-23 | 1992-07-23 | Novel treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9304435A true MX9304435A (en) | 1994-04-29 |
Family
ID=10719151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9304435A MX9304435A (en) | 1992-07-23 | 1993-07-22 | PHARMACEUTICAL COMPOSITION AND COMPOSITION FOR THE TREATMENT AND PROPHYLAXIS OF OBESITY OR FOR THE TREATMENT OF TYPE II DIABETES. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0651642A1 (en) |
JP (1) | JPH07509456A (en) |
CN (1) | CN1043610C (en) |
AU (1) | AU4714393A (en) |
GB (1) | GB9215633D0 (en) |
MX (1) | MX9304435A (en) |
TW (1) | TW258663B (en) |
WO (1) | WO1994002150A1 (en) |
ZA (1) | ZA935339B (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5783408A (en) * | 1995-06-07 | 1998-07-21 | Hamilton; Bradford S. | Method for screening potential anti-obesity agents |
PT1757606E (en) * | 2001-02-24 | 2009-05-26 | Boehringer Ingelheim Pharma | Xanthinderivatives for use as medical agents and the preparation thereof |
US6869947B2 (en) | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
WO2003004496A1 (en) * | 2001-07-03 | 2003-01-16 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
WO2003024965A2 (en) * | 2001-09-19 | 2003-03-27 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
DE10254304A1 (en) * | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New xanthine derivatives, their production and their use as medicines |
MXPA06002521A (en) | 2003-09-05 | 2006-06-20 | Altana Pharma Ag | Use of pde4 inhibitors for the treatment of diabetes mellitus. |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004030502A1 (en) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel imidazoles and triazoles, their preparation and use as medicines |
DE102004054054A1 (en) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines |
EP1874308A1 (en) | 2005-03-08 | 2008-01-09 | Nycomed GmbH | Roflumilast for the treatment of diabetes mellitus |
DE102005035891A1 (en) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals |
CA2873524C (en) | 2006-05-04 | 2018-02-20 | Boehringer Ingelheim International Gmbh | A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine |
PE20110235A1 (en) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20140960A1 (en) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | FORMULATIONS INVOLVING A DPP4 INHIBITOR |
BRPI0916997A2 (en) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | DPP-4 INHIBITOR AND ITS USE |
UY32030A (en) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN" |
CN102149407A (en) | 2008-09-10 | 2011-08-10 | 贝林格尔.英格海姆国际有限公司 | Combination therapy for the treatment of diabetes and related conditions |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
BRPI0923121A2 (en) | 2008-12-23 | 2015-08-11 | Boehringer Ingelheim Int | Saline forms of organic compounds |
AR074990A1 (en) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY |
CN102753161A (en) | 2009-11-27 | 2012-10-24 | 贝林格尔.英格海姆国际有限公司 | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
EP3124041A1 (en) | 2010-06-24 | 2017-02-01 | Boehringer Ingelheim International GmbH | Diabetes therapy |
AR083878A1 (en) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD |
ES2713566T3 (en) | 2011-07-15 | 2019-05-22 | Boehringer Ingelheim Int | Derivative of substituted dinamic quinazoline, its preparation and its use in pharmaceutical compositions for the treatment of type I and II diabetes |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
ES2950384T3 (en) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Medical use of a DPP-4 inhibitor |
JP2019517542A (en) | 2016-06-10 | 2019-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination of linagliptin and metformin |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8906792D0 (en) * | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
-
1992
- 1992-07-23 GB GB929215633A patent/GB9215633D0/en active Pending
-
1993
- 1993-07-21 AU AU47143/93A patent/AU4714393A/en not_active Abandoned
- 1993-07-21 EP EP93917883A patent/EP0651642A1/en not_active Withdrawn
- 1993-07-21 JP JP6504294A patent/JPH07509456A/en active Pending
- 1993-07-21 WO PCT/GB1993/001539 patent/WO1994002150A1/en not_active Application Discontinuation
- 1993-07-22 MX MX9304435A patent/MX9304435A/en unknown
- 1993-07-22 CN CN93116874A patent/CN1043610C/en not_active Expired - Lifetime
- 1993-07-23 ZA ZA935339A patent/ZA935339B/en unknown
- 1993-07-27 TW TW082105967A patent/TW258663B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU4714393A (en) | 1994-02-14 |
TW258663B (en) | 1995-10-01 |
WO1994002150A1 (en) | 1994-02-03 |
EP0651642A1 (en) | 1995-05-10 |
CN1043610C (en) | 1999-06-16 |
GB9215633D0 (en) | 1992-09-09 |
CN1114880A (en) | 1996-01-17 |
ZA935339B (en) | 1995-01-18 |
JPH07509456A (en) | 1995-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9304435A (en) | PHARMACEUTICAL COMPOSITION AND COMPOSITION FOR THE TREATMENT AND PROPHYLAXIS OF OBESITY OR FOR THE TREATMENT OF TYPE II DIABETES. | |
DE3587434D1 (en) | ANTIVIRAL PHARMACEUTICAL COMPOSITIONS AND THEIR USE. | |
KR890004709A (en) | Azithromycin and its derivatives as antiprotozoal agents | |
AR012671A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PROPHYLAXIS OF THE CONSTIPATION, THE USES OF SUCH COMPOSITIONS AND THE PROCESSES TO PREPARE THEM | |
KR960703009A (en) | Use of modafinil for the treatment of centrally-derived sleep apnea and dyspnea | |
ZA921538B (en) | Therapeutic compositions to protect and resuscitate mammalian cells and methods for preparing and using same | |
ES2172654T3 (en) | USE OF NSAID FOR THE TREATMENT OF SCALE CARCINOMAS OF THE ORAL OR OROPHARING CAVITY. | |
CA2002859A1 (en) | Method of treating epithelial disorders | |
PE13197A1 (en) | VENLAFAXINE IN THE TREATMENT OF HYPOTHALAMIC AMENORRHEA IN NON-DEPRESSED WOMEN | |
MY106067A (en) | Benzisothiazolinone-1-dioxide derivatives as elastase inhibitors. | |
NO940266L (en) | Internal radiation damage | |
AR247984A1 (en) | Anti-plaque compositions comprising a combination of morpholinoamino alcohol and chelating agent | |
MX9301387A (en) | METHOD AND COMPOSITION FOR THE TREATMENT OF OSTEOPOROSIS. | |
SE8904354D0 (en) | A PHARMACEUTICAL COMPOSITION | |
ES2092868T3 (en) | USE OF DERIVATIVES OF 4-THYORRESORCINE IN A COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION OF DEPIGMENTING ACTION. | |
BR0210744A (en) | Synergistically Pharmaceutical Combination for the Prevention or Treatment of Diabetes | |
DE3166111D1 (en) | Pharmaceutical composition for healing inflammatory and/or degenerative and/or atrophic mucous membranes | |
CO4130200A1 (en) | HELPFUL HIV PROTEASE INHIBITORS IN AIDS TREATMENT | |
MX9400040A (en) | COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS. | |
MX9302985A (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PROPHYLAXIS OF ANXIETY. | |
ES2088877T3 (en) | 3-PIRROLIDINOL PREPARATION PROCEDURE. | |
MD960168A (en) | Method for treatment of viral infections and compounds therefor | |
MX9300205A (en) | DISUBSTITUTED POLYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM. | |
MX9300203A (en) | DISUBSTITUTED POLYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM. | |
BR9810292A (en) | Diabetes treatment with thiazolidinedione, insulin secretagogue and alpha-glucosidase inhibitor |